Form 4: Clover Health CEO Sells Shares for Tax

Clover Health CEO Andrew Toy disposed of 308,950 Class A Common Stock shares on October 1, 2025, to cover tax obligations related to RSU vesting.

Summary

• Andrew Toy, Chief Executive Officer and Director of Clover Health Investments, Corp. (CLOV), reported a transaction involving company stock.
• On October 1, 2025, Toy disposed of 308,950 shares of Class A Common Stock.
• The disposition was made to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs).
• The shares were disposed of at a price of $2.62 per share.
• Following this transaction, Toy directly beneficially owns 10,165,562 shares of Class A Common Stock.
• This transaction relates to the vesting of 6.25% of the original RSUs granted on January 1, 2023, which was previously reported on a Form 4 filed on January 4, 2023.

Sentiment

Score: 5

Explanation: The transaction is a routine tax-related disposition of shares upon RSU vesting, which is a neutral event and does not reflect a discretionary sale or a change in the reporting person's confidence in the company.

Positives

• The continued vesting of RSUs and the reporting person's ongoing service as CEO and Director indicate sustained commitment to the company's leadership and future.

Negatives

• A reduction in direct beneficial ownership by 308,950 shares, although for tax purposes, slightly decreases insider holdings.

Future Outlook

Remaining Restricted Stock Units (RSUs) will continue to vest quarterly in equal installments of 6.25% until the final vesting date of January 1, 2027, contingent on Andrew Toy's continued service.

Industry Context

This Form 4 filing reports a routine insider transaction related to executive compensation and tax obligations, which is a common occurrence across all publicly traded companies and does not provide specific industry-wide insights.

Comparison to Industry Standards

• This filing details a standard insider transaction for tax withholding upon RSU vesting, a common practice for executives in publicly traded companies across various industries. No specific comparable companies, projects, or results are relevant for this type of filing.

Stakeholder Impact

• Shareholders: A minor, routine reduction in insider ownership, which is generally not considered a significant indicator of company performance or future prospects given the tax-related nature.
• Management: Andrew Toy continues in his role as CEO and Director, with ongoing RSU vesting tied to his continued service.

Next Steps

• Continued quarterly vesting of remaining Restricted Stock Units (RSUs) until January 1, 2027, subject to Andrew Toy's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by CEO Andrew Toy to cover tax obligations arising from RSU vesting. Such transactions are common for executives and are often pre-scheduled under Rule 10b5-1 plans. It does not indicate a change in management's outlook or the company's fundamentals, thus it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Clover Health, CLOV, Andrew Toy, Form 4, Insider Transaction, RSU Vesting, Stock Sale, Tax Withholding, CEO, Director, Beneficial Ownership